ArticleCritical care (London, England)2020
Plasma levels of the active form of suPAR are associated with COVID-19 severity.
Article in Critical care (London, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Endotheliopathy in Acute COVID-19 and Long COVID.International journal of molecular sciences · 2023Pooled it
- Novel inflammatory biomarkers in the prognosis of COVID-19.Therapeutic advances in respiratory diseasePooled it
- Soluble urokinase plasminogen activator receptor levels are predictive of COVID-19 severity in Afro-Caribbean patients.Biomarkers in medicine · 2022Trial
- Insight to Neglected Biomarkers in COVID-19: A Comprehensive Narrative Review".Biomarker insights · 2026Review
- Review
- Soluble Urokinase Plasminogen Activator Receptor: A Useful Marker for Predicting Mortality in COVID-19 Patients.Cureus · 2024Article
- Evaluation of Soluble Urokinase Plasminogen Activator Receptor in COVID-19 Patients.Journal of clinical medicine · 2024Article
- Circulating Soluble Urokinase Plasminogen Activator Receptor as a Predictive Indicator for COVID-19-Associated Acute Kidney Injury and Mortality: Clinical and Bioinformatics Analysis.International journal of molecular sciences · 2023Article
- Urokinase System in Pathogenesis of Pulmonary Fibrosis: A Hidden Threat of COVID-19.International journal of molecular sciences · 2023Article
- Detection of Inflammatory Biomarker suPAR in COVID-19 Disease With CHORUS TRIO Instrument.Biomarker insights · 2023Article
- The Association ofInternational journal of molecular sciences · 2022Article
- From Cytokine Storm to Cytokine Breeze: Did Lessons Learned from Immunopathogenesis Improve Immunomodulatory Treatment of Moderate-to-Severe COVID-19?Biomedicines · 2022Review
- Soluble urokinase Plasminogen Activator Receptor (suPAR) levels are predictive of COVID-19 severity: an Italian experience.Clinical immunology (Orlando, Fla.) · 2022Article
- suPAR: An Inflammatory Mediator for Kidneys.Kidney diseases (Basel, Switzerland) · 2022Review
- SCD14-ST and New Generation Inflammatory Biomarkers in the Prediction of COVID-19 Outcome.Biomolecules · 2022Article
- Comparison of the Mortality Prediction Value of Soluble Urokinase Plasminogen Activator Receptor (suPAR) in COVID-19 and Sepsis.Diagnostics (Basel, Switzerland) · 2022Article
- Utility of P-SEP, sTREM-1 and suPAR as Novel Sepsis Biomarkers in SARS-CoV-2 Infection.Indian journal of clinical biochemistry : IJCB · 2022Review
- suPAR to Risk-Stratify Patients With Malaria.Frontiers in immunology · 2022Review
- Endothelial, Immunothrombotic, and Inflammatory Biomarkers in the Risk of Mortality in Critically Ill COVID-19 Patients: The Role of Dexamethasone.Diagnostics (Basel, Switzerland) · 2021Article
- Soluble Urokinase Plasminogen Activator Receptor (suPAR) Independently Predicts Severity and Length of Hospitalisation in Patients With COVID-19.Frontiers in medicine · 2021Article
Corrections and comments
- Comment on
Authors and funding
8 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.